Kura Oncology (NASDAQ:KURA) has been given a consensus recommendation of “Buy” by the nine brokerages that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $22.00.
A number of research firms recently commented on KURA. Cann reissued a “buy” rating and set a $27.00 price objective on shares of Kura Oncology in a report on Thursday, April 5th. ValuEngine raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. BidaskClub downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Friday, March 23rd. Zacks Investment Research downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Thursday, March 22nd. Finally, Citigroup set a $28.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a report on Friday, February 16th.
Several hedge funds and other institutional investors have recently made changes to their positions in KURA. MetLife Investment Advisors LLC purchased a new stake in shares of Kura Oncology in the fourth quarter valued at about $155,000. American International Group Inc. lifted its holdings in shares of Kura Oncology by 42.0% in the fourth quarter. American International Group Inc. now owns 13,574 shares of the company’s stock valued at $208,000 after purchasing an additional 4,012 shares in the last quarter. California State Teachers Retirement System purchased a new stake in shares of Kura Oncology in the second quarter valued at about $235,000. Virtus Fund Advisers LLC purchased a new stake in shares of Kura Oncology in the fourth quarter valued at about $392,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Kura Oncology by 48.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 29,222 shares of the company’s stock valued at $447,000 after purchasing an additional 9,590 shares in the last quarter. 58.56% of the stock is currently owned by institutional investors.
KURA stock opened at $16.95 on Friday. Kura Oncology has a 52 week low of $5.90 and a 52 week high of $24.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.44 and a quick ratio of 9.44.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Monday, March 12th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). analysts expect that Kura Oncology will post -1.43 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Kura Oncology (KURA) Receives $22.00 Average PT from Analysts” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/17/kura-oncology-kura-receives-22-00-average-pt-from-analysts.html.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.